Thermo Fisher Scientific TMO recently received approval from the Food and Drug Administration (“FDA”) for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be ...
CARLSBAD, Calif.--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has granted approval to Thermo Fisher Scientific’s Oncomine Dx Target Test as a companion diagnostic (CDx) to aid in ...
Thermo Fisher Scientific Inc. TMO recently gained pre-market approval from the FDA for its Oncomine Dx Target Test as a companion diagnostic (CDx) to detect patients with epidermal growth factor ...
Oncomine Dx Express Test on the Ion Torrent Genexus Dx Integrated Sequencer generates results in as little as 24 hours to support timely therapy decisions A patient’s tumor profile has the potential ...
Prof. Hofman will present results of a multi-centric study evaluating performance of new Oncomine Dx Express Test, CE IVD for genomic profiling of cancer patient samples. The data cover performance ...
The FDA approved the Oncomine Dx Express Test for rapid identification of NSCLC patients eligible for Zegfrovy treatment. The test provides results in 24 hours, aiding timely therapeutic decisions and ...
The Oncomine Dx Target Test assesses tumor samples for the presence of biomarkers associated with three drug therapies approved to treat non-small cell lung cancer. Physicians can use the test to ...
Thermo Fisher Scientific Inc. is working with Daiichi Sankyo Co. Ltd. to develop a companion diagnostic (CDx) to identify non-small-cell lung cancer (NSCLC) patients with human epidermal growth factor ...
Dec 19 (Reuters) - Cancer Genetics Inc: * CANCER GENETICS RECEIVES NEW YORK STATE APPROVAL FOR FDA-APPROVED ONCOMINE DX TARGET TEST BY THERMO FISHER SCIENTIFIC Source text for Eikon: Further company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results